Management recommendations for patients with chronic kidney disease during the novel coronavirus disease 2019 (COVID-19) epidemic
COVID-19 has become a pandemic and it has already spread to at least 171 countries/regions. Chronic kidney disease (CKD) is a global public health problem with a total of approximately 850 million patients with CKD worldwide and 119.5 million in China. Severe COVID-19 infection may damage the kidney...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
KeAi Communications Co., Ltd.
2020-06-01
|
Series: | Chronic Diseases and Translational Medicine |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2095882X20300402 |
id |
doaj-b422c05ebc4e4a76b952dabeaca85184 |
---|---|
record_format |
Article |
spelling |
doaj-b422c05ebc4e4a76b952dabeaca851842021-04-02T12:30:33ZengKeAi Communications Co., Ltd.Chronic Diseases and Translational Medicine2095-882X2020-06-0162119123Management recommendations for patients with chronic kidney disease during the novel coronavirus disease 2019 (COVID-19) epidemicJuan Li0Shuang-Xi Li1Li-Fang Zhao2De-Liang Kong3Zhi-Yong Guo4Department of Nephrology, Changhai Hospital, Shanghai 200433, ChinaDepartment of Nephrology, Changhai Hospital, Shanghai 200433, ChinaDepartment of Nephrology, Changhai Hospital, Shanghai 200433, ChinaDepartment of Nephrology, Changhai Hospital, Shanghai 200433, ChinaCorresponding author. Department of Nephrology, Changhai Hospital, 168 Changhai Rd, Shanghai 200433, China.; Department of Nephrology, Changhai Hospital, Shanghai 200433, ChinaCOVID-19 has become a pandemic and it has already spread to at least 171 countries/regions. Chronic kidney disease (CKD) is a global public health problem with a total of approximately 850 million patients with CKD worldwide and 119.5 million in China. Severe COVID-19 infection may damage the kidney and cause acute tubular necrosis, leading to proteinuria, hematuria and elevated serum creatinine. Since the SARS-CoV-2 enters the cells by binding to the angiotensin-converting enzyme 2 receptor, some doctors question its ability to increase the risk and severity of developing COVID-19. Neither clinical data nor basic scientific evidence supports this assumption. Therefore, patients who take angiotensin-converting enzyme inhibitor or angiotensin receptor blocker are not advised to change their therapy. Patients with CKD are generally the elderly population suffering from multiple comorbidities. Moreover, some patients with CKD might need to take glucocorticoids and immunosuppressants. Dialysis patients are recurrently exposed to a possible contaminated environment because their routine treatment usually requires three dialysis sessions per week. Considering all the above reasons, patients with CKD are more vulnerable to COVID-19 than the general population. The development of COVID-19 may worsen the impaired kidney function and further lead to rapid deterioration of kidney function and even death. Strict comprehensive protocols should be followed to prevent the spread of COVID-19 among patients with CKD. In this review, we provide some practical management recommendations for health care providers, patients with CKD, dialysis patients and dialysis facilities.http://www.sciencedirect.com/science/article/pii/S2095882X20300402Coronavirus disease 2019COVID-19Novel coronavirusChronic kidney diseaseManagement |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Juan Li Shuang-Xi Li Li-Fang Zhao De-Liang Kong Zhi-Yong Guo |
spellingShingle |
Juan Li Shuang-Xi Li Li-Fang Zhao De-Liang Kong Zhi-Yong Guo Management recommendations for patients with chronic kidney disease during the novel coronavirus disease 2019 (COVID-19) epidemic Chronic Diseases and Translational Medicine Coronavirus disease 2019 COVID-19 Novel coronavirus Chronic kidney disease Management |
author_facet |
Juan Li Shuang-Xi Li Li-Fang Zhao De-Liang Kong Zhi-Yong Guo |
author_sort |
Juan Li |
title |
Management recommendations for patients with chronic kidney disease during the novel coronavirus disease 2019 (COVID-19) epidemic |
title_short |
Management recommendations for patients with chronic kidney disease during the novel coronavirus disease 2019 (COVID-19) epidemic |
title_full |
Management recommendations for patients with chronic kidney disease during the novel coronavirus disease 2019 (COVID-19) epidemic |
title_fullStr |
Management recommendations for patients with chronic kidney disease during the novel coronavirus disease 2019 (COVID-19) epidemic |
title_full_unstemmed |
Management recommendations for patients with chronic kidney disease during the novel coronavirus disease 2019 (COVID-19) epidemic |
title_sort |
management recommendations for patients with chronic kidney disease during the novel coronavirus disease 2019 (covid-19) epidemic |
publisher |
KeAi Communications Co., Ltd. |
series |
Chronic Diseases and Translational Medicine |
issn |
2095-882X |
publishDate |
2020-06-01 |
description |
COVID-19 has become a pandemic and it has already spread to at least 171 countries/regions. Chronic kidney disease (CKD) is a global public health problem with a total of approximately 850 million patients with CKD worldwide and 119.5 million in China. Severe COVID-19 infection may damage the kidney and cause acute tubular necrosis, leading to proteinuria, hematuria and elevated serum creatinine. Since the SARS-CoV-2 enters the cells by binding to the angiotensin-converting enzyme 2 receptor, some doctors question its ability to increase the risk and severity of developing COVID-19. Neither clinical data nor basic scientific evidence supports this assumption. Therefore, patients who take angiotensin-converting enzyme inhibitor or angiotensin receptor blocker are not advised to change their therapy. Patients with CKD are generally the elderly population suffering from multiple comorbidities. Moreover, some patients with CKD might need to take glucocorticoids and immunosuppressants. Dialysis patients are recurrently exposed to a possible contaminated environment because their routine treatment usually requires three dialysis sessions per week. Considering all the above reasons, patients with CKD are more vulnerable to COVID-19 than the general population. The development of COVID-19 may worsen the impaired kidney function and further lead to rapid deterioration of kidney function and even death. Strict comprehensive protocols should be followed to prevent the spread of COVID-19 among patients with CKD. In this review, we provide some practical management recommendations for health care providers, patients with CKD, dialysis patients and dialysis facilities. |
topic |
Coronavirus disease 2019 COVID-19 Novel coronavirus Chronic kidney disease Management |
url |
http://www.sciencedirect.com/science/article/pii/S2095882X20300402 |
work_keys_str_mv |
AT juanli managementrecommendationsforpatientswithchronickidneydiseaseduringthenovelcoronavirusdisease2019covid19epidemic AT shuangxili managementrecommendationsforpatientswithchronickidneydiseaseduringthenovelcoronavirusdisease2019covid19epidemic AT lifangzhao managementrecommendationsforpatientswithchronickidneydiseaseduringthenovelcoronavirusdisease2019covid19epidemic AT deliangkong managementrecommendationsforpatientswithchronickidneydiseaseduringthenovelcoronavirusdisease2019covid19epidemic AT zhiyongguo managementrecommendationsforpatientswithchronickidneydiseaseduringthenovelcoronavirusdisease2019covid19epidemic |
_version_ |
1721568767587123200 |